Sami Ullah Mumtaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sami Ullah Mumtaz has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Sajid Abaidullah
Department of Medicine, King Edward Medical University, Lahore 54000, Pakistan
4 shared publications - Somia Iqtadar
Associate Professor of Medicine, King Edward Medical University, Lahore, Pakistan
3 shared publications Zafar Niaz
King Edward Medical University Lahore
3 shared publications- Amjad Khan
Department of Oncology, University of Oxford, Oxford, United Kingdom
2 shared publications Iqra Waheed
Department of Microbiology, King Edward Medical University, Lahore
2 shared publicationsSajid Abaidullah
King Edward Medical University Lahore
2 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1202
Potential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study
Background/Objectives: Long COVID is characterised by persistent symptoms such as fatigue, pain, cognitive impairment, sleep disturbances, and reduced quality of life (QoL) following SARS-CoV-2 infection. Proposed mechanisms include persistent immune activation, chronic inflammation, oxidative stress, endothelial dysfunction, mitochondrial disturbances, and virus-induced cellular senescence. Current management is largely supportive, highlighting the need for complementary strategies targeting these pathways. Natural polyphenols such as quercetin and curcumin possess anti-inflammatory, antioxidant, immunomodulatory, and potential senolytic properties that may modulate multiple pathways implicated in Long COVID. This study aimed to explore the potential complementary effects of oral quercetin–curcumin co-supplementation, administered alongside usual symptomatic management, in adults with persistent Long COVID symptoms. Methods: This single-centre, open-label, single-arm, pragmatic exploratory study enrolled 15 adults with Long COVID in an outpatient real-life clinical practice setting. Participants received a nutraceutical formulation containing quercetin (65 mg) and Curcuma longa extract standardised to provide 42 mg curcumin (Nasafytol®), administered as two capsules twice daily for 8 weeks in addition to standard care. The primary endpoint was change in overall symptom burden assessed using the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). Secondary outcomes included fatigue (Fatigue Severity Scale, FSS), pain (Brief Pain Inventory—Short Form, BPI-SF), cognitive function (Patient-Reported Outcomes Measurement Information System Cognitive Function Short Form 8a, PROMIS-CF-8a), mood (Hospital Anxiety and Depression Scale, HADS), sleep quality (Pittsburgh Sleep Quality Index, PSQI), autonomic symptoms (Composite Autonomic Symptom Score-31, COMPASS-31), and health-related QoL (Medical Outcomes Study 36-Item Short-Form Health Survey, SF-36). Results: After 8 weeks, overall symptom burden significantly decreased (C19-YRS median 50 to 32; q = 0.018). Significant reductions were observed in patient-reported fatigue (q = 0.006), pain severity and interference (q = 0.006), and improved physical health-related QoL (SF-36 PCS; q = 0.025). Numerically favourable changes were also observed in cognitive function, anxiety, sleep quality, and autonomic symptoms, although these did not reach statistical significance. The supplementation was generally well tolerated with no serious adverse events. Conclusions: Quercetin–curcumin co-supplementation was associated with lower patient-reported symptom burden, fatigue, and pain and better physical health-related QoL after 8 weeks of supplementation in adults with Long COVID. These observed findings represent treatment-associated changes within this uncontrolled exploratory study and should be interpreted cautiously. Further evaluation in adequately powered randomised placebo-controlled trials is warranted. Trial registration: ClinicalTrials.gov (ID NCT06974058).
- 31 July 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1202
Open AccessPotential Adjunctive Effects of Quercetin–Curcumin Co-Supplementation in Adults with Mild-to-Moderate Long COVID: Results from a Pragmatic Exploratory Real-World Clinical Study
Background/Objectives: Long COVID is characterised by persistent symptoms such as fatigue, pain, cognitive impairment, sleep disturbances, and reduced quality of life (QoL) following SARS-CoV-2 infection. Proposed mechanisms include persistent immune activation, chronic inflammation, oxidative stress, endothelial dysfunction, mitochondrial disturbances, and virus-induced cellular senescence. Current management is largely supportive, highlighting the need for complementary strategies targeting these pathways. Natural polyphenols such as quercetin and curcumin possess anti-inflammatory, antioxidant, immunomodulatory, and potential senolytic properties that may modulate multiple pathways implicated in Long COVID. This study aimed to explore the potential complementary effects of oral quercetin–curcumin co-supplementation, administered alongside usual symptomatic management, in adults with persistent Long COVID symptoms. Methods: This single-centre, open-label, single-arm, pragmatic exploratory study enrolled 15 adults with Long COVID in an outpatient real-life clinical practice setting. Participants received a nutraceutical formulation containing quercetin (65 mg) and Curcuma longa extract standardised to provide 42 mg curcumin (Nasafytol®), administered as two capsules twice daily for 8 weeks in addition to standard care. The primary endpoint was change in overall symptom burden assessed using the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). Secondary outcomes included fatigue (Fatigue Severity Scale, FSS), pain (Brief Pain Inventory—Short Form, BPI-SF), cognitive function (Patient-Reported Outcomes Measurement Information System Cognitive Function Short Form 8a, PROMIS-CF-8a), mood (Hospital Anxiety and Depression Scale, HADS), sleep quality (Pittsburgh Sleep Quality Index, PSQI), autonomic symptoms (Composite Autonomic Symptom Score-31, COMPASS-31), and health-related QoL (Medical Outcomes Study 36-Item Short-Form Health Survey, SF-36). Results: After 8 weeks, overall symptom burden significantly decreased (C19-YRS median 50 to 32; q = 0.018). Significant reductions were observed in patient-reported fatigue (q = 0.006), pain severity and interference (q = 0.006), and improved physical health-related QoL (SF-36 PCS; q = 0.025). Numerically favourable changes were also observed in cognitive function, anxiety, sleep quality, and autonomic symptoms, although these did not reach statistical significance. The supplementation was generally well tolerated with no serious adverse events. Conclusions: Quercetin–curcumin co-supplementation was associated with lower patient-reported symptom burden, fatigue, and pain and better physical health-related QoL after 8 weeks of supplementation in adults with Long COVID. These observed findings represent treatment-associated changes within this uncontrolled exploratory study and should be interpreted cautiously. Further evaluation in adequately powered randomised placebo-controlled trials is warranted. Trial registration: ClinicalTrials.gov (ID NCT06974058).
- Open Access
- 31 May 2025
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Obesity and Life-Related Disorders
Obesity has turned into a global public health emergency with its impact on millions and causing a mass increase in life-style diseases encompassing type 2 diabetes, cardiovascular diseases, hypertension and others cancers. This pandemic is not only a personal health crisis, but also a societal issue that requires a holistic intervention that goes beyond effective cure and strong preventive strategies. Managing obesity and the related disorders demands a multi-faceted strategy. For the most severe, medical therapies (e.g, bariatric surgery) can achieve great weight loss and result in improvements of conditions including diabetes. In fact, progress has been made in the area pharmacotherapy with drugs like GLP-1 receptor agonists providing hope to treat a weight and metabolic health derangements. But, these therapies are expensive and don’t reach all especially in the low-income regions. At present, lifestyle interventions such as diet modifications and increased physical activity are the mainstays of obesity management. A few programs such as nutritional counseling integrated with exercise regimens have delivered sustainable results, although retention is a problem due to time constraints, loss of motivation, or socioeconomic disadvantages. Treatment is important above all, and prevention should be the number one goal to stop this obesity epidemic. Awareness-driven public health campaigns may increase knowledge of healthy eating and active living, but they need to be combined with systemic shifts. The government should set some policies to for example tax sugar-sweetened beverages and mandate clear nutritional label, subsidize fresh produce. Schools have a critical role by embedding nutrition education and physical activity into curriculums that encourage lifelong habits. Walkable cities, and access to recreational spaces through improving urban planning can also facilitate movement. Harmful social determinants of health are also addressed by community-based initiatives such as cooking or fitness groups that reach people who do not have the benefit of stronger support systems. Addressing basic factors of health will attend to social determinants of obesity. Obesity, exacerbated by poverty stress and poor healthcare access. Targeted community-level interventions, such as providing free or reduced-cost health screenings, can bring attention to and alleviate the problem prior to full-blown disease. For example, technology such as wearables and remote patient monitoring are being used to track health indicators and wellness behaviors. Obesity is a multifaceted problem that involves biology, environment and culture. Maybe treatments can, to some degree, decrease incidence but prevention driven policy and education with equitable access to resources has to be the answer if we want to stop this from dramatically increasing. Societies can reduce obesity and noncommunicable disease epidemics through health-promoting, empowering cultures that enable healthier lives.
- 31 May 2025
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Open AccessObesity and Life-Related Disorders
Obesity has turned into a global public health emergency with its impact on millions and causing a mass increase in life-style diseases encompassing type 2 diabetes, cardiovascular diseases, hypertension and others cancers. This pandemic is not only a personal health crisis, but also a societal issue that requires a holistic intervention that goes beyond effective cure and strong preventive strategies. Managing obesity and the related disorders demands a multi-faceted strategy. For the most severe, medical therapies (e.g, bariatric surgery) can achieve great weight loss and result in improvements of conditions including diabetes. In fact, progress has been made in the area pharmacotherapy with drugs like GLP-1 receptor agonists providing hope to treat a weight and metabolic health derangements. But, these therapies are expensive and don’t reach all especially in the low-income regions. At present, lifestyle interventions such as diet modifications and increased physical activity are the mainstays of obesity management. A few programs such as nutritional counseling integrated with exercise regimens have delivered sustainable results, although retention is a problem due to time constraints, loss of motivation, or socioeconomic disadvantages. Treatment is important above all, and prevention should be the number one goal to stop this obesity epidemic. Awareness-driven public health campaigns may increase knowledge of healthy eating and active living, but they need to be combined with systemic shifts. The government should set some policies to for example tax sugar-sweetened beverages and mandate clear nutritional label, subsidize fresh produce. Schools have a critical role by embedding nutrition education and physical activity into curriculums that encourage lifelong habits. Walkable cities, and access to recreational spaces through improving urban planning can also facilitate movement. Harmful social determinants of health are also addressed by community-based initiatives such as cooking or fitness groups that reach people who do not have the benefit of stronger support systems. Addressing basic factors of health will attend to social determinants of obesity. Obesity, exacerbated by poverty stress and poor healthcare access. Targeted community-level interventions, such as providing free or reduced-cost health screenings, can bring attention to and alleviate the problem prior to full-blown disease. For example, technology such as wearables and remote patient monitoring are being used to track health indicators and wellness behaviors. Obesity is a multifaceted problem that involves biology, environment and culture. Maybe treatments can, to some degree, decrease incidence but prevention driven policy and education with equitable access to resources has to be the answer if we want to stop this from dramatically increasing. Societies can reduce obesity and noncommunicable disease epidemics through health-promoting, empowering cultures that enable healthier lives.
- Open Access
- 27 March 2025
- Published by Pakistan Society of Gastroenterology and GI Endoscopy in Pakistan journal of Gastroenterology
- Vol. 41 (3) , 768-773
Gastrointestinal and hepatobiliary manifestations of COVID-19 infection: A single center study from Pakistan
BACKGROUND: Coronavirus disease was a global challenge affecting around 229 countries with over 700 million confirmed cases with significant morbidity and mortality. OBJECTIVE: To determine the frequency of hepatobiliary manifestations in patients of COVID-19. METHODOLOGY: This was a cross-sectional study conducted at North Medical Ward, Mayo Hospital, Lahore for three months. After ethical approval of the study, 200 COVID-19 RT-PCR positive cases of ages 15 to 80 years were included in the study. Complete history & examination regarding hepatobiliary symptoms were noted. Liver function tests & prothrombin time were sent to pathology laboratory & results were noted. Data was analyzed using SPSS-26. Quantitative variables like age, bilirubin, Aminotransferases & Prothrombin time were taken as mean ± standard deviation. Qualitative variables like gender, hepatobiliary symptoms were taken as frequency and percentages. RESULTS: The most common symptom at presentation was diarrhea 30 (15.0%) followed by fatigue, pruritic and anorexia 17 (8.5%), nausea, vomiting and abdominal pain 15 (7.5%), body petechiae & purpura in 13(6.5%), Right hypochondrial pain 11(5.5%) & Hiccup and dark color urine 1(0.5%). On laboratory findings,17(8.5%) patients had elevated bilirubin levels while AST was raised in 79(39.5%) of cases, ALT in 23(11.5%), Alkaline phosphatase in 6(3.0%), GGT in 95(47.5%) of cases. 8 (4.0%) cases showed decrease albumin level and 12(6.0%) cases had prolonged PT levels. CONCLUSION: Hepatobiliary symptoms and laboratory derangements are not uncommon in patients with COVID-19. So, attention should be given to these extra-pulmonary symptoms to avoid any delay in treatment & disease progression and complications.
- 27 March 2025
- Published by Pakistan Society of Gastroenterology and GI Endoscopy in Pakistan journal of Gastroenterology
- Vol. 41 (3) , 768-773
Open AccessGastrointestinal and hepatobiliary manifestations of COVID-19 infection: A single center study from Pakistan
BACKGROUND: Coronavirus disease was a global challenge affecting around 229 countries with over 700 million confirmed cases with significant morbidity and mortality. OBJECTIVE: To determine the frequency of hepatobiliary manifestations in patients of COVID-19. METHODOLOGY: This was a cross-sectional study conducted at North Medical Ward, Mayo Hospital, Lahore for three months. After ethical approval of the study, 200 COVID-19 RT-PCR positive cases of ages 15 to 80 years were included in the study. Complete history & examination regarding hepatobiliary symptoms were noted. Liver function tests & prothrombin time were sent to pathology laboratory & results were noted. Data was analyzed using SPSS-26. Quantitative variables like age, bilirubin, Aminotransferases & Prothrombin time were taken as mean ± standard deviation. Qualitative variables like gender, hepatobiliary symptoms were taken as frequency and percentages. RESULTS: The most common symptom at presentation was diarrhea 30 (15.0%) followed by fatigue, pruritic and anorexia 17 (8.5%), nausea, vomiting and abdominal pain 15 (7.5%), body petechiae & purpura in 13(6.5%), Right hypochondrial pain 11(5.5%) & Hiccup and dark color urine 1(0.5%). On laboratory findings,17(8.5%) patients had elevated bilirubin levels while AST was raised in 79(39.5%) of cases, ALT in 23(11.5%), Alkaline phosphatase in 6(3.0%), GGT in 95(47.5%) of cases. 8 (4.0%) cases showed decrease albumin level and 12(6.0%) cases had prolonged PT levels. CONCLUSION: Hepatobiliary symptoms and laboratory derangements are not uncommon in patients with COVID-19. So, attention should be given to these extra-pulmonary symptoms to avoid any delay in treatment & disease progression and complications.
- Open Access
- 31 January 2025
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
The Rise of Polycystic Kidney Disease (PKD): Early Detection and New Treatment Options
Polycystic Kidney Disease (PKD) is a hereditary disorder that results in the formation of fluid-filled cysts in the kidneys. Cysts can cause damage or worse renal failure over time. Although PKD has no cure, recent developments have helped in early detection and provided additional therapies that can control the condition and improve the quality of life of the affected. Early detection is essential to slow its progression and maintain renal function. It is inherited in an autosomal dominant pattern so the children of the afflicted parents have a 50% chance of developing this condition. The symptoms include kidney infections, flank pain, high blood pressure, and frequent urination, they don’t show up until later in life. Cyst formation may start sooner in childhood, and the condition may advance more quickly in certain instances. PKD can be confirmed by performing genetic testing in families with a history of the condition. Imaging methods such as MRI and ultrasound are essential in early diagnosis. Ultrasonography can be used to visualize the cyst. If this condition is diagnosed early medical professionals can treat the patient and control the symptoms while delaying kidney impairment. Some medications can delay its progression, but currently, no cure is there. There is a drug called Tolvaptan which inhibits the growth of kidney cysts and aids in maintaining renal function, is considered one of the noteworthy achievements. It has shown promising results in delaying the need for dialysis or kidney transplants by inhibiting the hormone vasopressin, a hormone responsible for the formation of cysts. Hypertension can worsen renal damage so drugs such as ACE inhibitors and angiotensin receptor blockers (ARBs) are prescribed to maintain blood pressure levels. Stem cell researchers are working on the repairing and renewal of damaged kidney tissue. Research on this subject has just started but the potential of this research can be foreseen in producing novel medicines that could revolutionize PKD care shortly. Life style plays an important role in controlling PKD, kidney strain can be reduced by maintaining a healthy life style, eating a diet that is low in proteins, and avoiding smoking. Frequent exercise can improve health and blood pressure. PKD is a health concern that affects people significantly but early detection and new treatments like tolyaptan and ongoing research are the hope for patients. Although no cure is available advancements in managing the disease can improve the quality of life and delay renal failure. With early intervention and the right treatment approach, PKD patients can lead healthier and more fulfilling lives.
- 31 January 2025
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Open AccessThe Rise of Polycystic Kidney Disease (PKD): Early Detection and New Treatment Options
Polycystic Kidney Disease (PKD) is a hereditary disorder that results in the formation of fluid-filled cysts in the kidneys. Cysts can cause damage or worse renal failure over time. Although PKD has no cure, recent developments have helped in early detection and provided additional therapies that can control the condition and improve the quality of life of the affected. Early detection is essential to slow its progression and maintain renal function. It is inherited in an autosomal dominant pattern so the children of the afflicted parents have a 50% chance of developing this condition. The symptoms include kidney infections, flank pain, high blood pressure, and frequent urination, they don’t show up until later in life. Cyst formation may start sooner in childhood, and the condition may advance more quickly in certain instances. PKD can be confirmed by performing genetic testing in families with a history of the condition. Imaging methods such as MRI and ultrasound are essential in early diagnosis. Ultrasonography can be used to visualize the cyst. If this condition is diagnosed early medical professionals can treat the patient and control the symptoms while delaying kidney impairment. Some medications can delay its progression, but currently, no cure is there. There is a drug called Tolvaptan which inhibits the growth of kidney cysts and aids in maintaining renal function, is considered one of the noteworthy achievements. It has shown promising results in delaying the need for dialysis or kidney transplants by inhibiting the hormone vasopressin, a hormone responsible for the formation of cysts. Hypertension can worsen renal damage so drugs such as ACE inhibitors and angiotensin receptor blockers (ARBs) are prescribed to maintain blood pressure levels. Stem cell researchers are working on the repairing and renewal of damaged kidney tissue. Research on this subject has just started but the potential of this research can be foreseen in producing novel medicines that could revolutionize PKD care shortly. Life style plays an important role in controlling PKD, kidney strain can be reduced by maintaining a healthy life style, eating a diet that is low in proteins, and avoiding smoking. Frequent exercise can improve health and blood pressure. PKD is a health concern that affects people significantly but early detection and new treatments like tolyaptan and ongoing research are the hope for patients. Although no cure is available advancements in managing the disease can improve the quality of life and delay renal failure. With early intervention and the right treatment approach, PKD patients can lead healthier and more fulfilling lives.
- Open Access
- 31 December 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Understanding Non-Hodgkin Lymphoma – A Growing Challenge in Cancer Care
Non-Hodgkin lymphoma is a type of blood cancer that originates in the lymphatic system a system very crucial for immune function. Unlike Hodgkin's Lymphoma, NHL is a group of cancers progressing at different rates, ranging from slow to fast. It originates in the lymphatic system making the diagnosis and treatment of this cancer particularly challenging, as each subtype requires a different approach. There rate of NHL has been increasing in recent years, and while the exact cause of this increasing number is still not clear there are factors that are contributing such as environmental influences, lifestyle changes, and an aging population. NHL affects people of all ages, but it is most commonly diagnosed in individuals ages 60 or older. One of the major issues in managing NHL is the symptoms that seem subtle, and are often mistaken for less serious conditions. Swollen lymph nodes, fever, night sweats, and unexplained weight loss are common signs of NHL but they can be attributed to other illnesses. As a result NHL is often diagnosed late which delays treatment and reduces the chances of successful outcomes. Recent advances in the treatment of NHL are promising. For fast-growing or the aggressive type chemotherapy remains the standard treatment, but some new therapies are making successful strides. Some therapies only focus on the cancerous cells and there is little damage done to the healthy tissues unlike chemotherapy which has proves to be more effective and less toxic Patients with refractory or relapsed NHL can be treated with immunotherapy which is the use of monoclonal antibodies and CAR T- cell therapy, strengthening the immune system to fight cancer more efficiently. The progress in the treatment of NHL is encouraging however early detection of it could be beneficial. There is imperative need for increased awareness of NHL symptoms. Research into the molecular and genetic underpinnings of NHL is also crucial for developing more precise treatments tailored to individual patients. A holistic approach is essential that addressing not just the physical needs but also the emotional needs of the patients. As healthcare providers, such as the oncologists, hematologists and pathologists collaborate their combined efforts can help improve survival rates as well as the quality of life. In conclusion, while the challenges of Non-Hodgkin lymphoma remain, advances in treatment, early detection, and patient care bring renewed optimism for those battling the disease.
- 31 December 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Open AccessUnderstanding Non-Hodgkin Lymphoma – A Growing Challenge in Cancer Care
Non-Hodgkin lymphoma is a type of blood cancer that originates in the lymphatic system a system very crucial for immune function. Unlike Hodgkin's Lymphoma, NHL is a group of cancers progressing at different rates, ranging from slow to fast. It originates in the lymphatic system making the diagnosis and treatment of this cancer particularly challenging, as each subtype requires a different approach. There rate of NHL has been increasing in recent years, and while the exact cause of this increasing number is still not clear there are factors that are contributing such as environmental influences, lifestyle changes, and an aging population. NHL affects people of all ages, but it is most commonly diagnosed in individuals ages 60 or older. One of the major issues in managing NHL is the symptoms that seem subtle, and are often mistaken for less serious conditions. Swollen lymph nodes, fever, night sweats, and unexplained weight loss are common signs of NHL but they can be attributed to other illnesses. As a result NHL is often diagnosed late which delays treatment and reduces the chances of successful outcomes. Recent advances in the treatment of NHL are promising. For fast-growing or the aggressive type chemotherapy remains the standard treatment, but some new therapies are making successful strides. Some therapies only focus on the cancerous cells and there is little damage done to the healthy tissues unlike chemotherapy which has proves to be more effective and less toxic Patients with refractory or relapsed NHL can be treated with immunotherapy which is the use of monoclonal antibodies and CAR T- cell therapy, strengthening the immune system to fight cancer more efficiently. The progress in the treatment of NHL is encouraging however early detection of it could be beneficial. There is imperative need for increased awareness of NHL symptoms. Research into the molecular and genetic underpinnings of NHL is also crucial for developing more precise treatments tailored to individual patients. A holistic approach is essential that addressing not just the physical needs but also the emotional needs of the patients. As healthcare providers, such as the oncologists, hematologists and pathologists collaborate their combined efforts can help improve survival rates as well as the quality of life. In conclusion, while the challenges of Non-Hodgkin lymphoma remain, advances in treatment, early detection, and patient care bring renewed optimism for those battling the disease.
- Open Access
- 30 November 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Strengthening Primary Healthcare in Pakistan: A Foundation for Sustainable Health Reform
The firsthand health care services and a set of health-improving strategies or interventions, underline the concept of public health care. These are for meeting the health needs of economically compromised groups of people fairly. This concept has been polished since 1978. Public health care does not only comprise the implementation of comprehensive healthcare approaches but also rising economic, environmental, and social concerns that can be useful in optimizing healthcare strategies. According to the Alma-Ata Declaration, PHC underscores the importance of focusing on all the health-improving aspects such as taking precautions for preventing illness to offering treatments, reducing morbidity rates, and improving survival rates [1]. Different regions of the world have different primary health care approaches which are being implemented strategically for the well-being of humankind. There are several challenges faced by the healthcare system in Pakistan such as insufficient funding, low healthcare workforce, and inadequate infrastructure. According to the World Health Organization (WHO), the health indicators of Pakistan are behind other countries in the continent, and the difference in the healthcare systems in the rural and urban areas is significant. A considerable portion of the population relies on the public sector for health facilities, as the private sector is way too expensive for an average person to afford. The core issue of the poor health care system in Pakistan is the financing so to strengthen it this must be addressed first. An increase in the spending in this department is imperative, especially in the rural and unprivileged areas where healthcare is not easily accessible. The difference between the healthcare systems in urban and rural areas can be decreased if there is an equitable distribution of resources. Moreover, training and retaining a skilled healthcare workforce could help resolve this issue. Programs such as Pakistan’s Lady Health Worker (LHW) have shown an increase in coverage but all these efforts can be supported by adequate resources and training. Health equity and primary health care go side by side. PHC ensures that healthcare is accessible not only to the privileged segment of society but also to marginalized populations, women, and children. By providing communities with these facilities Pakistan can take a great step towards achieving health coverage and improving the health of its population. In conclusion, strengthening PHC is not just an option it’s a demand and must be done. It’s the base for the achievement of sustainable health reforms. It should be prioritized by the policymakers, ensuring all Pakistanis get quality access to healthcare regardless of economic and geographic differences.
- 30 November 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01
Open AccessStrengthening Primary Healthcare in Pakistan: A Foundation for Sustainable Health Reform
The firsthand health care services and a set of health-improving strategies or interventions, underline the concept of public health care. These are for meeting the health needs of economically compromised groups of people fairly. This concept has been polished since 1978. Public health care does not only comprise the implementation of comprehensive healthcare approaches but also rising economic, environmental, and social concerns that can be useful in optimizing healthcare strategies. According to the Alma-Ata Declaration, PHC underscores the importance of focusing on all the health-improving aspects such as taking precautions for preventing illness to offering treatments, reducing morbidity rates, and improving survival rates [1]. Different regions of the world have different primary health care approaches which are being implemented strategically for the well-being of humankind. There are several challenges faced by the healthcare system in Pakistan such as insufficient funding, low healthcare workforce, and inadequate infrastructure. According to the World Health Organization (WHO), the health indicators of Pakistan are behind other countries in the continent, and the difference in the healthcare systems in the rural and urban areas is significant. A considerable portion of the population relies on the public sector for health facilities, as the private sector is way too expensive for an average person to afford. The core issue of the poor health care system in Pakistan is the financing so to strengthen it this must be addressed first. An increase in the spending in this department is imperative, especially in the rural and unprivileged areas where healthcare is not easily accessible. The difference between the healthcare systems in urban and rural areas can be decreased if there is an equitable distribution of resources. Moreover, training and retaining a skilled healthcare workforce could help resolve this issue. Programs such as Pakistan’s Lady Health Worker (LHW) have shown an increase in coverage but all these efforts can be supported by adequate resources and training. Health equity and primary health care go side by side. PHC ensures that healthcare is accessible not only to the privileged segment of society but also to marginalized populations, women, and children. By providing communities with these facilities Pakistan can take a great step towards achieving health coverage and improving the health of its population. In conclusion, strengthening PHC is not just an option it’s a demand and must be done. It’s the base for the achievement of sustainable health reforms. It should be prioritized by the policymakers, ensuring all Pakistanis get quality access to healthcare regardless of economic and geographic differences.
- Open Access
- 30 September 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01-02
Chronic Respiratory Diseases: Innovations in Treatment and Management
Chronic Respiratory Diseases (CRDs) include diseases of the airways and the lung and are among the major causes of morbidity and mortality worldwide. The major CRDs include asthma, chronic obstructive pulmonary disease (COPD), pulmonary sarcoidosis, pneumoconiosis and interstitial lung diseases (ILDs). The common symptoms of CRDs include wheezing, chest tightness, shortness of breath and cough [1]. These diseases affect millions of people across the globe and have significant impacts on patients’ quality of life and healthcare. Over the past few decades, however, improvement in the pharmacotherapy has provided a considerable progress. For example, biologics have given a new insight in the management of severe asthma by modulating certain inflammatory processes. Medications like omalizumab, dupilumab, and Mepolizumab are aimed at adjusting the immune response and significantly decrease the frequency of exacerbations and increase overall lung function. In addition, innovations in the field of stem cell therapy and tissue engineering are targeted to repair or replace diseased lung tissue, thus, being aimed at treating the origin of the diseases rather than simply alleviating the symptoms. Furthermore, Nanoparticles can be orally given, intravenously injected or inhaled using nanoparticle aerosols. Nanoparticles can also be used in the molecular imaging of chronic lung diseases such as COPD. Advanced inhalers, developed with sensors, can monitor the usage of medication and provide feedback in real-time to ensure compliance to prescriptions and other salient treatment plans. COPD pulmonary rehabilitation programs of exercise and education together with psychological support for individuals have been documented to enhance quality of life. The use of AI and a machine learning system has now moved to the ability to forecast disease exacerbations and provide individualized recommendations for treatment of CRDs. As a result, people with COPD receive care through various healthcare professions like doctors, nurses, and physiotherapists, which may have diverse roles, such as prescribing medications, supporting their self‐management or patient education, or delivering exercise training. The aim of an Integrated Disease Management (IDM) programme is that various aspects of care through which healthcare providers are working in coordination to deliver improved and optimum care to patients. Similarly Advancements in the treatment of ILD are being conducted, and recently, some new FDA-approved drugs have been advised for the management of patients. Among these are Nintedanib is a tyrosine kinase inhibitor, Pirfenidone an anti-fibrotic and anti-thrombotic agent and Treprostinil is an analogue of prostacyclin. These drugs have opened a new path for the treatment of ILD and have improved the recovery outcomes of patients [2]. Rituximab has also been found to be effective in more than half of patients treated in a small prospective open-label trial of refractory pulmonary disease in sarcoidosis[3]. Overall, there is a renewed emphasis on CRD management as a burgeoning field. With the advancement in the research in the personalized, proactive and integrative strategy the efforts made will lay down new avenues of better health outcomes for millions of people suffering from the CRDs. The future of respiratory health is bright as it is a growing field that has no sign of discontinuing its steady development and pushing for the comforts and breakthroughs for many patients across the globe.
- 30 September 2024
- Published by CrossLinks International Publishers in Pakistan Journal of Health Sciences
- p. 01-02
Open AccessChronic Respiratory Diseases: Innovations in Treatment and Management
Chronic Respiratory Diseases (CRDs) include diseases of the airways and the lung and are among the major causes of morbidity and mortality worldwide. The major CRDs include asthma, chronic obstructive pulmonary disease (COPD), pulmonary sarcoidosis, pneumoconiosis and interstitial lung diseases (ILDs). The common symptoms of CRDs include wheezing, chest tightness, shortness of breath and cough [1]. These diseases affect millions of people across the globe and have significant impacts on patients’ quality of life and healthcare. Over the past few decades, however, improvement in the pharmacotherapy has provided a considerable progress. For example, biologics have given a new insight in the management of severe asthma by modulating certain inflammatory processes. Medications like omalizumab, dupilumab, and Mepolizumab are aimed at adjusting the immune response and significantly decrease the frequency of exacerbations and increase overall lung function. In addition, innovations in the field of stem cell therapy and tissue engineering are targeted to repair or replace diseased lung tissue, thus, being aimed at treating the origin of the diseases rather than simply alleviating the symptoms. Furthermore, Nanoparticles can be orally given, intravenously injected or inhaled using nanoparticle aerosols. Nanoparticles can also be used in the molecular imaging of chronic lung diseases such as COPD. Advanced inhalers, developed with sensors, can monitor the usage of medication and provide feedback in real-time to ensure compliance to prescriptions and other salient treatment plans. COPD pulmonary rehabilitation programs of exercise and education together with psychological support for individuals have been documented to enhance quality of life. The use of AI and a machine learning system has now moved to the ability to forecast disease exacerbations and provide individualized recommendations for treatment of CRDs. As a result, people with COPD receive care through various healthcare professions like doctors, nurses, and physiotherapists, which may have diverse roles, such as prescribing medications, supporting their self‐management or patient education, or delivering exercise training. The aim of an Integrated Disease Management (IDM) programme is that various aspects of care through which healthcare providers are working in coordination to deliver improved and optimum care to patients. Similarly Advancements in the treatment of ILD are being conducted, and recently, some new FDA-approved drugs have been advised for the management of patients. Among these are Nintedanib is a tyrosine kinase inhibitor, Pirfenidone an anti-fibrotic and anti-thrombotic agent and Treprostinil is an analogue of prostacyclin. These drugs have opened a new path for the treatment of ILD and have improved the recovery outcomes of patients [2]. Rituximab has also been found to be effective in more than half of patients treated in a small prospective open-label trial of refractory pulmonary disease in sarcoidosis[3]. Overall, there is a renewed emphasis on CRD management as a burgeoning field. With the advancement in the research in the personalized, proactive and integrative strategy the efforts made will lay down new avenues of better health outcomes for millions of people suffering from the CRDs. The future of respiratory health is bright as it is a growing field that has no sign of discontinuing its steady development and pushing for the comforts and breakthroughs for many patients across the globe.
- 27 June 2023
- Published by Weston Medical Publishing in Journal of Emergency Management
- Vol. 21 (3) , 241-252
Stress levels among healthcare workers and adult population during the third wave of COVID-19 pandemic in a metropolitan city
Introduction: The impact of coronavirus disease 2019 (COVID-19) on public health has been widespread with clinically diverse manifestations ranging from asymptomatic presentation to critical illness. COVID-19 might influence different aspects of the stress process on the general population and healthcare workers (HCWs). Objectives: To examine the relationship of demographic variables with depression, anxiety, and stress and to compare stress levels in HCWs and the general population. Method: A cross-sectional study was conducted. A sample of 1,063 participants was collected based on two groups. The first group comprised of HCWs who were directly looking after COVID-19 confirmed or suspected patients and working in any primary, secondary, or tertiary care hospitals. The second group comprised of participants working in public-dealing departments or businesses. Depression Anxiety Stress Scale-42 (DASS-42) was administered to assess depression, anxiety, and stress. Result: Young people, females, and people having less work experience and without civil defense or disaster management training were more depressed, anxious, and stressed. Participants who had no access to scientific journals were more stressed. Average time spent on social media on COVID-19-related information, history of psychological illnesses, and use of sedatives after the COVID-19 pandemic positively predicted anxiety, depression, and stress. There was no significant difference in the scores of depression, anxiety, and stress for HCWs and the general population. Conclusion: The anxiety levels were comparable among HCWs and adults, with vulnerable groups being female gender, young adults, and those who had a previous history of depression or substance abuse. Special consideration must be given to mental health, and protocols must be designed to provide psychological and emotional support to susceptible individuals.
- 27 June 2023
- Published by Weston Medical Publishing in Journal of Emergency Management
- Vol. 21 (3) , 241-252
Stress levels among healthcare workers and adult population during the third wave of COVID-19 pandemic in a metropolitan city
Introduction: The impact of coronavirus disease 2019 (COVID-19) on public health has been widespread with clinically diverse manifestations ranging from asymptomatic presentation to critical illness. COVID-19 might influence different aspects of the stress process on the general population and healthcare workers (HCWs). Objectives: To examine the relationship of demographic variables with depression, anxiety, and stress and to compare stress levels in HCWs and the general population. Method: A cross-sectional study was conducted. A sample of 1,063 participants was collected based on two groups. The first group comprised of HCWs who were directly looking after COVID-19 confirmed or suspected patients and working in any primary, secondary, or tertiary care hospitals. The second group comprised of participants working in public-dealing departments or businesses. Depression Anxiety Stress Scale-42 (DASS-42) was administered to assess depression, anxiety, and stress. Result: Young people, females, and people having less work experience and without civil defense or disaster management training were more depressed, anxious, and stressed. Participants who had no access to scientific journals were more stressed. Average time spent on social media on COVID-19-related information, history of psychological illnesses, and use of sedatives after the COVID-19 pandemic positively predicted anxiety, depression, and stress. There was no significant difference in the scores of depression, anxiety, and stress for HCWs and the general population. Conclusion: The anxiety levels were comparable among HCWs and adults, with vulnerable groups being female gender, young adults, and those who had a previous history of depression or substance abuse. Special consideration must be given to mental health, and protocols must be designed to provide psychological and emotional support to susceptible individuals.
- Open Access
- 5 January 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (1) , 43
Vitamin D Deficiency (VDD) and Susceptibility towards Severe Dengue Fever—A Prospective Cross-Sectional Study of Hospitalized Dengue Fever Patients from Lahore, Pakistan
Dengue is a mosquito-borne flaviviral serious febrile illness, most common in the tropical and subtropical regions including Pakistan. Vitamin D is a strong immunomodulator affecting both the innate and adaptive immune responses and plays a pivotal role in pathogen-defense mechanisms. There has been considerable interest in the possible role of vitamin D in dengue viral (DENV) infection. In the present prospective cross-sectional study, we assessed a possible association between serum vitamin D deficiency (VDD) and susceptibility towards severe dengue fever (DF) illness. Serum vitamin D levels were measured at the time of hospitalization in 97 patients diagnosed with dengue fever (DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) at Mayo Hospital, King Edward Medical University, Lahore, PK, from 16 November 2021 to 15 January 2022. In terms of disease severity, 37 (38.1%) patients were DF, 52 (53.6%) were DHF grade 1 and 2, and 8 (8.2%) were DSS. The results revealed that most patients (75 (77.3%)) were vitamin-D-deficient (i.e., serum level < 20 ng/mL), including 27 (73.0%) in DF, 41 (78.8%) in DHF grade 1 and 2, and 7 (87.5%) in DSS. The degree of VDD was somewhat higher in DSS patients as compared to DF and DHF grade 1 and 2 patients. Overall, serum vitamin D levels ranged from 4.2 to 109.7 ng/mL, and the median (IQR) was in the VDD range, i.e., 12.2 (9.1, 17.8) ng/mL. Our results suggest that there may be a possible association between VDD and susceptibility towards severe dengue illness. Hence, maintaining sufficient vitamin D levels in the body either through diet or supplementation may help provide adequate immune protection against severe dengue fever illness. Further research is warranted.
- 5 January 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (1) , 43
Open AccessVitamin D Deficiency (VDD) and Susceptibility towards Severe Dengue Fever—A Prospective Cross-Sectional Study of Hospitalized Dengue Fever Patients from Lahore, Pakistan
Dengue is a mosquito-borne flaviviral serious febrile illness, most common in the tropical and subtropical regions including Pakistan. Vitamin D is a strong immunomodulator affecting both the innate and adaptive immune responses and plays a pivotal role in pathogen-defense mechanisms. There has been considerable interest in the possible role of vitamin D in dengue viral (DENV) infection. In the present prospective cross-sectional study, we assessed a possible association between serum vitamin D deficiency (VDD) and susceptibility towards severe dengue fever (DF) illness. Serum vitamin D levels were measured at the time of hospitalization in 97 patients diagnosed with dengue fever (DF), dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) at Mayo Hospital, King Edward Medical University, Lahore, PK, from 16 November 2021 to 15 January 2022. In terms of disease severity, 37 (38.1%) patients were DF, 52 (53.6%) were DHF grade 1 and 2, and 8 (8.2%) were DSS. The results revealed that most patients (75 (77.3%)) were vitamin-D-deficient (i.e., serum level < 20 ng/mL), including 27 (73.0%) in DF, 41 (78.8%) in DHF grade 1 and 2, and 7 (87.5%) in DSS. The degree of VDD was somewhat higher in DSS patients as compared to DF and DHF grade 1 and 2 patients. Overall, serum vitamin D levels ranged from 4.2 to 109.7 ng/mL, and the median (IQR) was in the VDD range, i.e., 12.2 (9.1, 17.8) ng/mL. Our results suggest that there may be a possible association between VDD and susceptibility towards severe dengue illness. Hence, maintaining sufficient vitamin D levels in the body either through diet or supplementation may help provide adequate immune protection against severe dengue fever illness. Further research is warranted.
- Open Access
- 28 September 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (10) , 1926
Clinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study
Anatomical and physiological considerations indicate that the oral cavity is a primary source of the lung microbiota community, and recent studies have shown that the microbiota in the lungs contributes to immunological homeostasis, potentially altering the organ’s susceptibility to viral infection, including SARS-CoV-2. It has been proposed that, in the case of viral infection, lung Gram-negative bacteria could promote the cytokine cascade with a better performance than a microbiota mainly constituted by Gram-positive bacteria. Recent observations also suggest that Prevotella-rich oral microbiotas would dominate the oral cavity of SARS-CoV-2-infected patients. In comparison, Streptococcus-rich microbiotas would dominate the oral cavity of healthy people. To verify if the modulation of the oral microbiota could have an impact on the current coronavirus disease, we administered for 14 days a well-recognized and oral-colonizing probiotic (S. salivarius K12) to hospitalized COVID-19 patients. The preliminary results of our randomized and controlled trial seem to prove the potential role of this oral strain in improving the course of the main markers of pathology, as well as its ability to apparently reduce the death rate from COVID-19. Although in a preliminary and only circumstantial way, our results seem to confirm the hypothesis of a direct involvement of the oral microbiota in the construction of a lung microbiota whose taxonomic structure could modulate the inflammatory processes generated at the pulmonary and systemic level by a viral infection.
- 28 September 2022
- Published by MDPI AG in Microorganisms
- Vol. 10 (10) , 1926
Open AccessClinical Effects of Streptococcus salivarius K12 in Hospitalized COVID-19 Patients: Results of a Preliminary Study
Anatomical and physiological considerations indicate that the oral cavity is a primary source of the lung microbiota community, and recent studies have shown that the microbiota in the lungs contributes to immunological homeostasis, potentially altering the organ’s susceptibility to viral infection, including SARS-CoV-2. It has been proposed that, in the case of viral infection, lung Gram-negative bacteria could promote the cytokine cascade with a better performance than a microbiota mainly constituted by Gram-positive bacteria. Recent observations also suggest that Prevotella-rich oral microbiotas would dominate the oral cavity of SARS-CoV-2-infected patients. In comparison, Streptococcus-rich microbiotas would dominate the oral cavity of healthy people. To verify if the modulation of the oral microbiota could have an impact on the current coronavirus disease, we administered for 14 days a well-recognized and oral-colonizing probiotic (S. salivarius K12) to hospitalized COVID-19 patients. The preliminary results of our randomized and controlled trial seem to prove the potential role of this oral strain in improving the course of the main markers of pathology, as well as its ability to apparently reduce the death rate from COVID-19. Although in a preliminary and only circumstantial way, our results seem to confirm the hypothesis of a direct involvement of the oral microbiota in the construction of a lung microbiota whose taxonomic structure could modulate the inflammatory processes generated at the pulmonary and systemic level by a viral infection.